Current Environment: Production

Recall Alert

There is an antibacterial antibiotic recall. Read more →

Education

Medical School

SUNY Downstate College of Medicine

2010, Brooklyn, NY

Residency

NY Presbyterian Hospital – Weill Cornell Medical Center

2013, New York, NY

Fellowship

University of Washington School of Medicine / Seattle Children’s Hospital

2016, Seattle, WA

Education

Undergraduate School

Bombay University

Bombay, India

Medical School

T. N. Medical College, Bombay University

Bombay, India

Residency

Lincoln Hospital & Medical Center / New York Medical College

Bronx, NY

Fellowship

Maria Fareri Children’s Hospital

Valhalla, NY

Education

Undergraduate School

City College of New York

1973, New York, NY

Medical School

New York Medical College

1978, Valhalla, NY

Residency

Cornell Medical Center

1981, New York, NY

Fellowship

Cornell Medical Center

1984, New York, NY

Education

Undergraduate School

George Washington University

1993, Washington, DC

Medical School

George Washington University

1998, Washington, DC

Residency

NYU Medical Center

2001, New York, NY

Fellowship

Columbia Presbyterian Hospital

2004, New York, NY

Education

Medical School

Emory University

1999, Atlanta, GA

Residency

Emory University School of Medicine

2003, Atlanta, GA

Fellowship

Aflac Cancer Center and Blood Disorders Service

Emory University School of Medicine

2005, Atlanta, GA

Publications

  1. Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703. Blood Adv. 2025 Apr 30. View Abstract

  2. Accurate prediction of absolute prokaryotic abundance from DNA concentration. Cell Rep Methods. 2025 May 19; 5(5):101030. View Abstract

  3. Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant. medRxiv. 2025 Feb 26. View Abstract

  4. Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD. Blood. 2025 Feb 03. View Abstract

  5. Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease. Sci Transl Med. 2025 Jan 29; 17(783):eads1298. View Abstract

  6. Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 Mar 10; 43(8):912-918. View Abstract

  7. Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. Blood. 2024 10 24; 144(17):1834-1845. View Abstract

  8. Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. Sci Transl Med. 2024 Oct 16; 16(769):eadj9331. View Abstract

  9. Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024 Sep; 59(9):1335. View Abstract

  10. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nat Biotechnol. 2024 Aug 21. View Abstract

  11. B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates. Blood. 2024 07 04; 144(1):46-60. View Abstract

  12. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice. Blood. 2024 05 23; 143(21):2201-2216. View Abstract

  13. Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation. J Clin Invest. 2024 Apr 15; 134(8). View Abstract

  14. The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities. Transplant Cell Ther. 2025 Feb; 31(2):109.e1-109.e13. View Abstract

  15. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024 Jun; 59(6):832-837. View Abstract

  16. Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD. Bone Marrow Transplant. 2024 May; 59(5):680-687. View Abstract

  17. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Blood. 2023 08 24; 142(8):700-710. View Abstract

  18. Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis. Blood Adv. 2023 08 22; 7(16):4395-4399. View Abstract

  19. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 08 22; 7(16):4647-4657. View Abstract

  20. Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis. Bone Marrow Transplant. 2023 11; 58(11):1260-1263. View Abstract

  21. Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies. Bone Marrow Transplant. 2023 11; 58(11):1264-1266. View Abstract

  22. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Adv. 2023 07 25; 7(14):3725-3734. View Abstract

  23. Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates. Sci Transl Med. 2023 06 28; 15(702):eadd1175. View Abstract

  24. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023 06 22; 388(25):2338-2348. View Abstract

  25. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023 May 24. View Abstract

  26. Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure. Blood Adv. 2023 05 23; 7(10):2196-2205. View Abstract

  27. Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation. Mol Ther Methods Clin Dev. 2023 Jun 08; 29:483-493. View Abstract

  28. Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208. View Abstract

  29. Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity. Am J Transplant. 2023 08; 23(8):1102-1115. View Abstract

  30. Case Report: The First Case Report of Visceral Leishmaniasis in Cambodia. Am J Trop Med Hyg. 2022 08 17; 107(2):336-338. View Abstract

  31. Retinoic acid signaling acts as a rheostat to balance Treg function. Cell Mol Immunol. 2022 07; 19(7):820-833. View Abstract

  32. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997. View Abstract

  33. Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. Blood Adv. 2022 02 08; 6(3):746-749. View Abstract

  34. Identification and Tracking of Alloreactive T Cell Clones in Rhesus Macaques Through the RM-scTCR-Seq Platform. Front Immunol. 2021; 12:804932. View Abstract

  35. Myelopathy Because of CAR-T-Related Neurotoxicity Treated With Siltuximab. Neurol Clin Pract. 2021 Dec; 11(6):e944-e946. View Abstract

  36. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 11; 27(11):885-907. View Abstract

  37. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649. View Abstract

  38. Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. J Clin Invest. 2021 06 15; 131(12). View Abstract

  39. Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Adv. 2021 06 08; 5(11):2519-2522. View Abstract

  40. Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy. 2021 08; 23(8):704-714. View Abstract

  41. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood. 2021 02 25; 137(8):1090-1103. View Abstract

  42. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 06 10; 39(17):1865-1877. View Abstract

  43. Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus-host disease. Sci Transl Med. 2021 01 13; 13(576). View Abstract

  44. Measurement of leukocyte trafficking kinetics in macaques by serial intravascular staining. Sci Transl Med. 2021 01 13; 13(576). View Abstract

  45. Creating an international network for science and clinical progress: democratizing dissemination of advances in global hematology. Blood Adv. 2021 01 12; 5(1):275-276. View Abstract

  46. Current Concepts and Advances in Graft-Versus-Host Disease Immunology. Annu Rev Immunol. 2021 04 26; 39:19-49. View Abstract

  47. Author Correction: Innovations present in the primate interneuron repertoire. Nature. 2020 Dec; 588(7837):E17. View Abstract

  48. End the pain: Start with antiracism. Am J Hematol. 2021 01; 96(1):4-6. View Abstract

  49. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood. 2020 10 08; 136(15):1722-1734. View Abstract

  50. Isolation of a Highly Purified HSC-enriched CD34+CD90+CD45RA- Cell Subset for Allogeneic Transplantation in the Nonhuman Primate Large-animal Model. Transplant Direct. 2020 Aug; 6(8):e579. View Abstract

  51. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Blood Adv. 2020 06 09; 4(11):2536-2547. View Abstract

  52. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease. Gastroenterology. 2020 08; 159(2):591-608.e10. View Abstract

  53. IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer. Blood Adv. 2020 04 28; 4(8):1594-1605. View Abstract

  54. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 05 28; 181(5):1016-1035.e19. View Abstract

  55. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatr Blood Cancer. 2020 04; 67(4):e28134. View Abstract

  56. Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model. Mol Ther. 2019 09 04; 27(9):1586-1596. View Abstract

  57. Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease. Pediatr Blood Cancer. 2019 05; 66(5):e27601. View Abstract

  58. Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. Nat Commun. 2018 10 25; 9(1):4438. View Abstract

  59. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. J Clin Invest. 2018 08 31; 128(9):3991-4007. View Abstract

  60. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018 09 27; 132(13):1438-1451. View Abstract

  61. Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis. Blood. 2018 06 14; 131(24):2630-2639. View Abstract

  62. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther. 2018 06 06; 26(6):1423-1434. View Abstract

  63. Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. Cancer Discov. 2018 06; 8(6):750-763. View Abstract

  64. Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. 2018 03; 24(3S):S15-S19. View Abstract

  65. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340. View Abstract

  66. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. 2018 01; 24(1):27-31. View Abstract

  67. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20; 9(408). View Abstract

  68. In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. Am J Transplant. 2017 Dec; 17(12):3098-3113. View Abstract

  69. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev. 2017 03; 276(1):192-212. View Abstract

  70. A Canine Model of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):420-427. View Abstract

  71. Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease. Transplantation. 2016 Dec; 100(12):2630-2639. View Abstract

  72. Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. Blood. 2016 11 24; 128(21):2568-2579. View Abstract

  73. The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques. Am J Transplant. 2017 03; 17(3):657-670. View Abstract

  74. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016 07 01; 126(7):2642-60. View Abstract

  75. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015 Nov 25; 7(315):315ra191. View Abstract

  76. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015 Dec; 90(12):1135-41. View Abstract

  77. Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1845-52. View Abstract

  78. Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease. Br J Haematol. 2015 Jul; 170(2):247-56. View Abstract

  79. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRß repertoire. Blood. 2015 Jun 18; 125(25):3835-50. View Abstract

  80. Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. Br J Haematol. 2015 May; 169(4):574-83. View Abstract

  81. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant. 2014 Dec; 14(12):2691-703. View Abstract

  82. Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog. 2014 Sep; 10(9):e1004406. View Abstract

  83. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant. 2014 May; 14(5):1142-51. View Abstract

  84. CD8-predominant T-cell CNS infiltration accompanies GVHD in primates and is improved with immunoprophylaxis. Blood. 2014 Mar 20; 123(12):1967-9. View Abstract

  85. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1638-49. View Abstract

  86. Heterologous immunity triggered by a single, latent virus in Mus musculus: combined costimulation- and adhesion- blockade decrease rejection. PLoS One. 2013; 8(8):e71221. View Abstract

  87. Pluripotent stem cells: immune to the immune system? Sci Transl Med. 2012 Dec 12; 4(164):164ps25. View Abstract

  88. Cooking up tolerance: has a new recipe been created? Am J Transplant. 2012 Jul; 12(7):1667-9. View Abstract

  89. Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant. 2012 Jul; 12(7):1755-64. View Abstract

  90. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant. 2012 Jun; 12(6):1441-57. View Abstract

  91. Nonhuman primate transplant models finally evolve: detailed immunogenetic analysis creates new models and strengthens the old. Am J Transplant. 2012 Apr; 12(4):812-9. View Abstract

  92. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood. 2011 Dec 15; 118(25):6580-90. View Abstract

  93. CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant. 2012 Jan; 12(1):115-25. View Abstract

  94. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion. 2012 Feb; 52(2):231-40. View Abstract

  95. An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant. 2010 Nov; 10(11):2396-409. View Abstract

  96. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. Blood. 2010 Dec 09; 116(24):5403-18. View Abstract

  97. Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses. Am J Transplant. 2008 Nov; 8(11):2252-64. View Abstract

  98. Expansion of effector memory TCR Vbeta4+ CD8+ T cells is associated with latent infection-mediated resistance to transplantation tolerance. J Immunol. 2008 Mar 01; 180(5):3190-200. View Abstract

  99. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin- and Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant. 2007 Aug; 7(8):1884-96. View Abstract

  100. Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation. 2007 Jul 27; 84(2):196-206. View Abstract

  101. Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression. Am J Transplant. 2007 Feb; 7(2):320-35. View Abstract

  102. Transplant tolerance in non-human primates: progress, current challenges and unmet needs. Am J Transplant. 2006 May; 6(5 Pt 1):884-93. View Abstract

  103. NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant. 2006 Feb; 6(2):292-304. View Abstract

  104. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood. 2003 Dec 15; 102(13):4582-93. View Abstract

  105. Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. Exp Hematol. 2002 May; 30(5):394-402. View Abstract

  106. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood. 2002 Mar 01; 99(5):1840-9. View Abstract

  107. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001 Jul 15; 167(2):1103-11. View Abstract

Education

Undergraduate School

Colgate University

Hamilton, NY

Medical School

University of Michigan

Ann Arbor, MI

Internship

Boston Combined Residency Program (BCRP)

Boston, MA

Residency

Boston Combined Residency Program (BCRP)

Boston, MA

Education

Undergraduate School

Worcester Polytechnic Institute

Worcester, MA

Medical School

New York Medical College

Valhalla, NY

Internship

Yale-New Haven Hospital

New Haven, CT

Education

Undergraduate School

Williams College

1998, Williamstown, MA

Medical School

University of Rochester School of Medicine and Dentistry

2003, Rochester, NY

Residency

Boston Combined Residency Program (BCRP)

2004, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2006, Boston, MA

Publications

Education

Medical School

University of Heidelberg

1985, Heidelberg, Germany

Internship

Children’s Hospital of University of Heidelberg

Heidelberg, Germany

Residency

Pediatrics

Boston Children's Hospital

1993, MA

Fellowship

Pediatric Infectious Diseases

Boston Children's Hospital

1998, Boston, MA

Publications
Subscribe to English

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services